IP Library › Granted Patent US 11,241,479
Granted Patent B2
US 11,241,479 · App. 16/995,042 · Granted Feb 8, 2022

Treatment methods using botulinum toxins

Inventor: Roland M. Williams (Beaumont, TX)
Assignee: Penland Foundation
A61K38/164A61K9/0019A61K38/4893A61P29/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,241,479
App. No.
16/995,042
Granted
Feb 8, 2022
Kind
B2
Abstract

A method of tolerance to narcotics in a patient in need thereof comprises administering a botulinum toxin to the patient. The botulinum toxin is selected from the group consisting of botulinum toxin type A, botulinum toxin type B, botulinum toxin type C, botulinum toxin type D, botulinum toxin type E, botulinum toxin type F and botulinum toxin type G, a fragment thereof, a hybrid thereof, a chimera thereof, and a combination thereof. The botulinum toxin may be administered by subcutaneous/intradermal injection. The subcutaneous/intradermal injection may be administered to and/or around the vicinity of a trigeminal nerve, a cervical nerve, a thoracic nerve, a lumbar nerve, and a sacral nerve of the patient. The therapeutically effective amount of the botulinum toxin administered is between about 1 unit and about 150 units.

Claims (12)

1. A method of treating tolerance to narcotics in a patient in need thereof who is necessitated to be on long term narcotic use, comprising administering a botulinum toxin to the patient, thereby treating the tolerance to narcotics,

wherein the administering for an adult comprises by subcutaneous or intradermal injection 2-4 units to and/or around the vicinity of a trigeminal nerve, 2-4 units to and/or around the vicinity of a cervical nerve, lateral to the patient's spine, 2-4 units to and/or around the vicinity of a thoracic nerve, lateral to the spine, 2-4 units to and/or around the vicinity of a lumbar nerve, lateral to the spine, and 2-4 units to and/or around the vicinity of a sacral nerve, lateral to the spine.

2. The method of claim 1 , wherein the trigeminal nerve is selected from the group consisting of an ophthalmic nerve, maxillary nerve, mandibular nerve, supra orbital nerve, supra trochlear nerve, infraorbital nerve, lacrimal nerve, nasociliary nerve, superior alveolar nerve, buccal nerve, lingual nerve, inferior alveolar nerve, mental nerve, an auriculotemporal nerve, lesser occipital nerve, a greater occipital nerve and a combination thereof.

3. The method of claim 1 , wherein the cervical nerve is selected from the group consisting of a c-2 nerve, c-3 nerve, c-4 nerve, c-5 nerve, c-6 nerve, c-7 nerve, c-8 nerve and a combination thereof.

4. The method of claim 1 , wherein the botulinum toxin is selected from the group consisting of botulinum toxin type A, botulinum toxin type B, botulinum toxin type C, botulinum toxin type D, botulinum toxin type E, botulinum toxin type F and botulinum toxin type G, a fragment thereof, a hybrid thereof, a chimera thereof, and a combination thereof.

5. The method of claim 1 , wherein each of the subcutaneous or intradermal injection is bilateral.

6. The method of claim 1 wherein tolerance to narcotics in the patient is reduced.

7. The method of claim 1 , wherein a total dosage of the botulinum toxin for an adult who weighs about 150 lbs is between about 50 and about 150 units.

8. The method of claim 7 , wherein a total dosage of the botulinum toxin for an adult, a child over about 5 years old and a toddler about from 1 to 5 years old is adjusted for age, weight or a combination thereof.

9. The method of claim 1 , wherein the thoracic nerve is selected from the group consisting of a t-2 nerve, t-3 nerve, t-5 nerve, t-6 nerve, t-7 nerve, t-8 nerve, t-9 nerve, t-10 nerve, t-11 nerve, t-12 nerve and a combination thereof.

10. The method of claim 1 , wherein the lumbar nerve is selected from the group consisting of a 1-1 nerve, 1-2 nerve, 1-3 nerve, 1-4 nerve, 1-5 nerve and a combination thereof.

11. The method of claim 1 , wherein the sacral nerve is selected from the group consisting of a s-1 nerve, s-2 nerve, s-3 nerve, s-4 nerve, s-5 nerve and a combination thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2020
From: WILLIAMS, ROLAND M.
To: PENLAND FOUNDATION
Reel/Frame 053544/0929 →
Continuity (2)
Continuation 16657950 · Oct 18, 2019
Related Publication 20210187063A1 · Jun 24, 2021